Blend CJC 1295 NO DAC 5mg with GHRP-6 5mg
Buy 2 Get 1 Free Blend CJC 1295 NO DAC 5mg with GHRP-6 5mg :
| Unit Size | 10 mg/vial |
| Unit Quantity | 1 vial |
| Purity (Mass Spectrometry and UV) | 99.38% Nominal Target: 5 mg CJC 1295 NO DAC + 5 mg GHRP-6 |
| Sequence (CJC 1295 NO DAC) | H-Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu- Ser-Ala-Arg-Lys-Leu--Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2 |
| Sequence (GHRP 6) | H-His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 |
| Molecular Formula (CJC 1295 NO DAC) |
C152H252N44O42 |
| Molecular Formula (GHRP 6) | C46H55N12O6 |
| Appearance | Lyophilized White Powder |
| Source | Chemical Synthesis |
| Storage | Lyophilized Blend CJC 1295 NO DAC with GHRP-6 is stable at roomTemperature for 90 days, however it is best to store in a freezer below - 8c for any extended period of time. |
| Terms | The products we offer are intended for laboratory research use only. Please familiarize yourself with our terms of service prior to ordering. |
Blend CJC-1295 NO-DAC 5mg with GHRP-6 5mg
View Research Overview & References
CJC-1295 NO-DAC with GHRP-6 combines a synthetic analog of growth hormone-releasing hormone (GHRH) with growth hormone-releasing peptide-6 (GHRP-6). CJC-1295 is derived from GHRH 1-29 (sermorelin) and consists of 30 amino acids with a molecular weight of 3647.16 g/mol. This formulation does not contain a drug affinity complex (DAC), resulting in a shorter half-life than the DAC-bound version.1
Animal Model Research
In an animal model study using GHRH-deficient mice, research examined CJC-1295's effects on growth hormone (GH) and IGF-1-related signaling.2 GHRP-6, a synthetic ghrelin analog, is studied for its interaction with the growth hormone secretagogue receptor (GHS-R), relevant to research on GH-related signaling pathways. Research has examined this peptide combination for its effects on baseline and pulsatile growth hormone secretion patterns in animal models.
Tissue Repair Marker Research
Animal model research has examined GHRP-6's effects on tissue repair markers and scar tissue formation in wound models.3,4 Separate animal model research has examined markers of neuronal signaling in models of induced cerebral ischemia in combination with recombinant epidermal growth factor (rhEGF).5
Important Notice
CJC-1295 NO-DAC with GHRP-6 is strictly intended for in vitro and in vivo (animal) laboratory research and is not for human or animal use, diagnostic use, or therapeutic purposes. This product has not been evaluated for safety or efficacy in humans or animals. Researchers utilize this product to investigate growth hormone-related signaling and tissue-repair marker mechanisms in experimental settings.
Product Information
This peptide combination is supplied as a lyophilized powder at a concentration of 10 mg per vial (5 mg x 2).
References
1. Jette L, Leger R, Thibaudeau K, et al. Human Growth Hormone-Releasing Factor (hGRH) 1-29 - Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long-Lasting GRF Analog. Endocrinology. 2005 Jul;146(7):3052-3058.
2. Alba M, Fintini D, Sagazio A, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006 Dec;291(6):E1290-4.
3. Mayola MF, Betancourt L, Molina-Kautzman A, et al. Growth hormone-releasing peptide 6 prevents cutaneous hypertrophic scarring: early mechanistic data from a proteome study. Int Wound J. 2018 Aug;15(4):538-546.
4. Mari YM, Mayola MF, Barreto AA, et al. Growth Hormone-Releasing Peptide 6 Enhances the Healing Process and Improves the Esthetic Outcome of the Wounds. Plast Surg Int. 2016;2016:4361702.
5. Subiros N, Perez-Saad HM, Berlanga JA, et al. Assessment of dose-effect and therapeutic time window in preclinical studies of rhEGF and GHRP-6 coadministration for stroke therapy. Neurol Res. 2016 Mar;38(3):187-95.
Storage Case (10)$9.99
